SCHEMBL3377331

SCHEMBL3377331

CN(CC1CC(Oc2ccc(CN3CCCC3)c(Cl)c2)C1)C(=O)c1ccccc1F

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.51
HRH1 P35367 4/20 0.43
CCR3 P51677 4/20 0.43
KCNH2 Q12809 3/20 0.43
KMT2A Q03164 3/20 0.41
POLB P06746 1/20 0.39
ADRB2 P07550 1/20 0.39
MLNR O43193 1/20 0.38
MEN1 O00255 2/20 0.37
BLM P54132 1/20 0.37
S1PR1 P21453 1/20 0.36
PRKX P51817 1/20 0.36
ACVR1 Q04771 1/20 0.36
S1PR5 Q9H228 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3376855 0.93 HRH3 (0.49) HRH3HRH1CCR3KCNH2KMT2A
SCHEMBL3376700 0.91 HRH3 (0.50) HRH3HRH1CCR3KCNH2ADRB2
SCHEMBL3377382 0.91 HRH3 (0.50) HRH3HRH1CCR3KCNH2KMT2A
SCHEMBL3375240 0.88 HRH3 (0.54) HRH3HRH1CCR3KCNH2KMT2A
SCHEMBL3376243 0.87 HRH3 (0.50) HRH3HRH1CCR3KCNH2KMT2A
SCHEMBL3377337 0.86 HRH3 (0.51) HRH3HRH1CCR3KCNH2KMT2A
SCHEMBL3375319 0.86 HRH3 (0.52) HRH3HRH1CCR3KCNH2POLB
SCHEMBL3380151 0.86 HRH3 (0.52) HRH3HRH1CCR3KCNH2POLB
SCHEMBL3380634 0.86 HRH3 (0.49) HRH3HRH1CCR3KCNH2KMT2A
SCHEMBL3377277 0.86 HRH3 (0.49) HRH3HRH1CCR3KCNH2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899296-B1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2010-11-17 EP claimed
US-7812040-B2 such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders PFIZER INC. (US) 2010-10-12 US claimed
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER INC. (US) 2009-05-21 US claimed
EP-1899296-B1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2010-11-17 EP disclosed
US-7812040-B2 such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders PFIZER INC. (US) 2010-10-12 US disclosed
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER INC. (US) 2009-05-21 US disclosed
EP-1899296-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2008-03-19 EP disclosed
WO-2006136924-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131433-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS HRH3, HRH4, HRH2 HRH3 1/4885HRH1 4/4885CCR3 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.